Clinical Trials · NCT05212857
Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Unknown
- Sponsor
- Fudan University
- Enrollment
- 160
- Start date
- Apr 2022
- Locations
- 1 site, China
- Primary endpoint
- Two years' radiographic progression-free survival (rPFS)